NUVECTIS PHARMA INC NVCT
COM · Common Stock · CUSIP 67080T108
- SectorHealth care
- IndustryPharmaceutical Preparations
- HeadquartersFort Lee, NJ
- FilingsSEC EDGAR
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Shares outstanding: 14.6m as of 2022-11-07, from the company's own SEC filing; the percentage can still exceed 100%: lent-out shares are counted by the lender and the buyer, and some reports overlap without saying so. Implied quarter-end price ≈ $7.09.
Major shareholders (over 5%)
Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.
| Holder | Stake |
|---|---|
| Soleus Private Equity Fund III, L.P. 13G · passive investor new · filed 2026-08-06 | 5.1% |
Insider purchases and sales in Q3 2022
Shares bought or sold by the company's own officers, directors and 10% owners, in the open market or privately, as they reported to the SEC on Form 4 (due within two business days of the trade). Grants, option exercises, shares withheld for tax and gifts aren't included.
Officers and directors buying vs selling
Number of people, by quarter (10% owners not included)
Numbers
| Quarter | Buying | Bought | Selling | Sold | Sold under a plan |
|---|---|---|---|---|---|
| Q4 2020 | 0 | — | 0 | — | — |
| Q1 2021 | 0 | — | 0 | — | — |
| Q2 2021 | 0 | — | 0 | — | — |
| Q3 2021 | 0 | — | 0 | — | — |
| Q4 2021 | 0 | — | 0 | — | — |
| Q1 2022 | 3 | $1.4m | 0 | — | — |
| Q2 2022 | 5 | $565.3k | 0 | — | — |
| Q3 2022 | 2 | $410.1k | 0 | — | — |
| Date | Insider | Trade | Value |
|---|---|---|---|
| 2022-09-30 | BENTSUR RON Chairman & CEO, director | Bought | $3.7k500 shares |
| 2022-09-28 | BENTSUR RON Chairman & CEO, director | Bought | $3.6k500 shares |
| 2022-09-26 | BENTSUR RON Chairman & CEO, director | Bought | $3.8k500 shares |
| 2022-09-23 | BENTSUR RON Chairman & CEO, director | Bought | $7.9k1.0k shares |
| 2022-09-23 | Shemesh Shay Chief Dev. & Ops. Officer | Bought | $1.7k220 shares |
| 2022-09-02 | BENTSUR RON Chairman & CEO, director | Bought | $10.0k1.2k shares |
| 2022-09-02 | Shemesh Shay Chief Dev. & Ops. Officer | Bought | $3.4k404 shares |
| 2022-09-01 | Shemesh Shay Chief Dev. & Ops. Officer | Bought | $12.3k1.5k shares |
| 2022-09-01 | BENTSUR RON Chairman & CEO, director | Bought | $4.1k500 shares |
| 2022-08-31 | Shemesh Shay Chief Dev. & Ops. Officer | Bought | $11.9k1.5k shares |
| 2022-08-29 | BENTSUR RON Chairman & CEO, director | Bought | $9.1k1.0k shares |
| 2022-08-23 | BENTSUR RON Chairman & CEO, director | Bought | $4.5k500 shares |
| 2022-08-19 | BENTSUR RON Chairman & CEO, director | Bought | $45.0k5.0k shares |
| 2022-08-18 | BENTSUR RON Chairman & CEO, director | Bought | $123.8k14.4k shares |
| 2022-08-11 | BENTSUR RON Chairman & CEO, director | Bought | $165.2k19.7k shares |
Their holding: how much the trade added to or took from the insider's holding (direct, or the trust or fund named). The same trade is sometimes reported by more than one insider, such as a fund and the director who represents it; totals count it once. A value is left blank where the reported price is far from the market price (usually a typo).
Holders, Q3 2022
| Manager | Shares | Change |
|---|---|---|
| SABBY MANAGEMENT, LLC 9.46% of their portfolio | 633.0k $4.5m | — |
| Ronit Capital LLP 5.43% of their portfolio | 562.5k $4.0m | — |
| BALDWIN WEALTH PARTNERS LLC/MA 0.13% of their portfolio | 133.0k $943.0k | — |
| GEODE CAPITAL MANAGEMENT, LLC 0.00% of their portfolio | 31.4k $222.0k | — |
| VANGUARD GROUP INC 0.00% of their portfolio | 27.1k $192.0k | — |
| BlackRock Inc. 0.00% of their portfolio | 14.0k $100.0k | — |
| STATE STREET CORP 0.00% of their portfolio | 11.7k $83.0k | — |
| Tower Research Capital LLC (TRC) 0.00% of their portfolio | 4.1k $29.0k | — |
| UBS Group AG 0.00% of their portfolio | 220 $2.0k | — |
| MORGAN STANLEY 0.00% of their portfolio | 201 $1.0k | — |
| ROYAL BANK OF CANADA 0.00% of their portfolio | 76 $1.0k | — |
| WELLS FARGO & COMPANY/MN 0.00% of their portfolio | 24 $0 | — |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. 0.00% of their portfolio | 0 $0 | — |